| Unique stem cell line identifier | 1) SCVIi134-A 2) SCVIi137-A |
|
| |
| Alternative name(s) of stem cell lines | 1) SCVI 692 (SCVIi134-A) 2) SCVI 770 (SCVIi137-A) |
| Institution | Stanford Cardiovascular Institute |
| Contact information of the distributor | Joseph C. Wu |
| Type of cell lines | iPSCs |
| Origin | Human |
| Additional origin info is required for human ESC or iPSC | Age: 60 (SCVIi134-A), 64 (SCVIi137-A), Sex: Female (both lines), Ethnicity if known: White (both lines) |
| Cell Source | PBMC |
| Clonality | Clonal |
| Method of reprogramming | Sendai virus vectors |
| Genetic Modification | Yes |
| Type of Genetic Modification | Spontaneous mutation |
| Evidence of the reprogramming transgene loss (including genomic copy if applicable) | RT-qPCR |
| Associated disease | Myotonic Dystrophy Type 1 (DM1, OMIM ID: 160900) |
| Gene/locus | DMPK, 19q13.32, CTG repeat expansion |
| Date archived/stock date | 1) 11/18/2022 (SCVIi134-A) 2) 01/06/2021 (SCVIi137-A) |
| Cell line repository/bank | SCVi134-A: https://hpscreg.eu/cell-line/SCVIi134-A SCVi137-A: https://hpscreg.eu/cell-line/SCVIi137-A |
| Ethical approval | The Administrative Panel on Human Subjects Research (IRB) granted approval for the lines’ production under IRB #29904, “Derivation of Human-Induced Pluripotent Stem Cells (Biorepository). |